Global Zellweger Spectrum Disorders Market, By Type (Heimler Syndrome, Infantile Refsum Disease, Neonatal Adrenoleukodystrophy, Zellweger Syndrome), Therapy (Pediatricians, Neurologists, Surgeons, Audiologists, Ophthalmologists, Orthopedists), Diagnosis (Blood Test, Urine Test, Ultrasound, Genetic Test), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Zellweger Spectrum Disorders Market Analysis and Size
The global zellweger spectrum disorders market is expected to witness significant growth during the forecast period. Zellweger spectrum disorder consists of Heimler Syndrome, Infantile Refsum Disease and Neonatal Adrenoleukodystrophy. With several new advances coming up in genomics, different ways to treat and manage zellweger spectrum disorders in a way that gives the minimum discomfort to the victims of this disorder are being researched and trialled. It is studied that the PEX1 gene has a mutation that causes tis syndrome in the majority of instances and they affect approximately 1 in 50,000 to 1 in 75,000 babies, along with the several other disorders on the Zellweger spectrum.
Data Bridge Market Research analyses a growth rate in the global zellweger spectrum disorders market in the forecast period 2022-2029. The expected CAGR of global zellweger spectrum disorders market is tend to be around 6% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Zellweger Spectrum Disorders Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Heimler Syndrome, Infantile Refsum Disease, Neonatal Adrenoleukodystrophy, Zellweger Syndrome), Therapy (Pediatricians, Neurologists, Surgeons, Audiologists, Ophthalmologists, Orthopedists), Diagnosis (Blood Test, Urine Test, Ultrasound, Genetic Test), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Centogene N.V. (Germany), Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BioMarin (U.S.), Sarepta Therapeutics (U.S.), Siemens Healthcare GmbH (U.S.), Blueprint Genetics Oy (Finland), General Electric (U.S.), Koninklijke Philips N.V. (Netherlands), Hitachi, Ltd (Japan), GeneDx, LLC (U.S.), Asper Biogene LLC (Estonia)
|
|
Market Opportunities
|
|
Market Definition
Zellweger spectrum is a rare type of disorder, also known as peroxisome biogenesis disorders (PBDs), and is typically characterized as the body's failure to produce peroxisomes. This disease is caused by the defects in one of the 13 genes known as PEX genes which are significant for the normal formation and function of peroxisomes. The symptoms include hypotonia, neurological deficits, hearing and vision issues, liver and kidney abnormalities.
Global Zellweger Spectrum Disorders Market Dynamics
Drivers
- Rising Research on Rare Diseases
ZSD was a rare illness about which not much was known. Although, because of increasing research spending, clinical knowledge is now improving. This is expected to encourage early diagnosis of the condition and is projected to help in developing suitable treatment strategies. For instance, investment in the U.S.'s medical and health research and development (R&D) increased by 11% to around USD245 billion in 2020 from 2019. This boosts the market growth.
- Increased Clinical Studies and Government Initiatives
The global metabolic syndrome market is estimated to be driven by rising R&D investments in drug discovery and development and the rising prevalence of diabetes. For instance, for the treatment of diabetes as a metabolic syndrome, as per the reports of the International Diabetes Federation, around 415 million people are currently affected by diabetes globally and it is hoped to increase to 642 million diabetic people by the year 2040.
Opportunities
- Increasing Demand for Retail Pharmacies
Rise in the number of metabolic syndromes therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Increased Healthcare Expenditure
The healthcare professionals are increasingly interested in conducting active research to find solutions for many rare diseases such as Zellweger spectrum disorder as they want to be prepared for any comparable occurrence in the future as the chances of developing diseases in children are increasing.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could limit the growth of the global zellweger spectrum disorders market over a forecast period.
- High Cost
The huge expenditure of treatment methods hamper the market growth. The higher cost of genetic tests are predicted to boost the segment growth. For instance, the price of genetic testing varies from USD100 to more than USD2,000 per test. The price rises high if all of the members are getting tested. Thus, increasing prices are hampering the growth of the market.
This global zellweger spectrum disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global zellweger spectrum disorders market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Zellweger Spectrum Disorders Market
The Covid-19 pandemic negatively impacted the global zellweger spectrum disorders market because the utmost priority was given to Covid-19 patients for treatment. Several medical colleges and hospitals were reorganized and helped in the structure so that they can accommodate more patients diagnosed with Covid-19. This disorder is pretty rare as 1 in 50,000 new-borns get affected due to ZSD. The novel coronavirus has moved the entire globe and hence in, finding a cure against it has enhanced the research and development faction. Discovery and development of drugs for the types of metabolic syndromes also slowed down during the pandemic, but surely it wasn’t in a pause and now in the post-pandemic era, it is rising again.
Global Zellweger Spectrum Disorders Market Scope
The global zellweger spectrum disorders market is segmented on the basis of therapy, type, diagnosis, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Heimler Syndrome
- Infantile Refsum Disease
- Neonatal Adrenoleukodystrophy
- Zellweger Syndrome
Therapy
- Pediatricians
- Neurologists
- Surgeons
- Audiologists
- Ophthalmologists
- Orthopedists
Diagnosis
- Blood Test
- Urine Test
- Ultrasound,
- Genetic Test
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Zellweger Spectrum Disorders Market Regional Analysis/Insights
The global zellweger spectrum disorders market is analyzed and market size insights and trends are provided by therapy, type, diagnosis, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global zellweger spectrum disorders market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the increasing research and development activities, advancing diagnostics, growing initiatives for the screening test of new-borns, more collaborations and growing awareness.
Asia-Pacific dominates the market due to the presence of major key players, advanced research, well-developed healthcare infrastructure, mandatory screening test of new-borns and increasing awareness towards health in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Zellweger Spectrum Disorders Market Share Analysis
The global zellweger spectrum disorders market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global zellweger spectrum disorders market.
Key players operating in the global zellweger spectrum disorders market include:
- Centogene N.V. (Germany)
- Hoffmann-La Roche Ltd. (Switzerland)
- PerkinElmer Inc (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BioMarin (U.S.)
- Sarepta Therapeutics (U.S.)
- Siemens Healthcare GmbH (U.S.)
- Blueprint Genetics Oy (Finland)
- General Electric (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- Hitachi, Ltd (Japan),
- GeneDx, LLC (U.S.)
- Asper Biogene LLC (Estonia)
SKU-